RARE - Company ID 0001515673
The table below shows Ultragenyx Pharmaceutical Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$197.00M | -$166.00M | -$190.73M | -$156.87M | -$117.52M | -$159.35M |
| Capital expenditure | $1.00M | $1.00M | $3.21M | $25.03M | $32.18M | $16.41M |
| Investing cash flow | -$49.00M | $120.00M | $94.44M | $111.30M | -$37.36M | -$182.42M |
| Dividends paid | - | - | - |
Ultragenyx Pharmaceutical Inc. reported operating cash flow of -$466.00M for fiscal year 2025. That is down 12.6% from -$414.00M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$160.97M (FY 2016) to -$466.00M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | - | $157.00K | -$58.00K | -$722.00K | $1.61M | $12.65M |